Company: TYRA
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0000950170-25-046124
Chunk: 192

Company: Tyra Biosciences, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1B
Chunk 192
---
3, respectively. Accrued interest receivable is included in prepaid expenses and other current assets on the Company's balance sheets. We have not written off any accrued interest receivables for the years ended December 31, 2024 and 2023.

4. Property and EquipmentProperty and equipment consisted of the following (in thousands): 

        December 31,2024

        December 31,2023

        Equipment
         
        $
        1,875

        $
        1,443

        Computers and software

        205

        208

        Leasehold improvements

        469

        402

        Furniture and fixtures

        383

        382

        2,932

        2,435

        Less: accumulated depreciation

        (1,281
        )

        (807
        )

        Total property and equipment, net
         
        $
        1,651

        $
        1,628

       The Company recognized $0.5 million and $0.4 million in depreciation expense for the years ended December 31, 2024 and 2023, respectively.

128

5. Accrued Expenses and Other Current LiabilitiesAccrued expenses and other current liabilities consisted of the following (in thousands): 

        December 31,2024

        December 31,2023

        Accrued payroll and other employee benefits
         
        $
        6,451

        $
        5,117

        Accrued research and development expenses

        6,612

        4,848

        Accrued legal and professional fees

        296

        132

        Accrued other general and administrative fees

        233

        294

        Total accrued and other current liabilities
         
        $
        13,592

        $
        10,391

6. Stockholders' EquityCommon Stock Common stock reserved for future issuance consisted of the following:

        December 31,2024

        December 31,2023

        Common stock options granted and outstanding

        10,462,129

        8,276,442

        Shares available for future issuance under the 2021   Incentive Award Plan

        3,051,588

        3,677,313

        Shares available for future issuance under the    2021 Employee Stock Purchase Plan